All In Biotech

Free tool

FAERS Monitor: Draximage Dtpa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018511 or its brand name (Draximage Dtpa, Technetium Tc-99m Pentetate Kit). Reports on generic versions are filed under their own applications.

Reports

13

Serious

3

23% of reports

Hospitalization

1

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective6
  • dyspnoea2
  • product ineffective2
  • blood pressure increased1
  • cns ventriculitis1
  • confusional state1
  • erythema1
  • feeling hot1
  • foetal heart rate deceleration abnormality1
  • headache1
  • hypersensitivity1
  • incorrect route of product administration1
  • lethargy1
  • malaise1
  • meningitis chemical1

Reports by year received

View as table
YearReports
20181
20192
20201
20211
20222
20242
20253
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
meningitis chemical17395.21119.71,839
cns ventriculitis14983.2755.71,241
product ineffective24131.51152.44,633
foetal heart rate deceleration abnormality12297.2348.9573
incorrect route of product administration194.414.423
lethargy128.14.36
feeling hot126.44.06
blood pressure increased110.61.62
confusional state110.01.52
hypersensitivity18.71.31
erythema17.91.21
drug ineffectiveSignal67.44.129
dyspnoea25.71.64
malaise13.70.60
headache12.60.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.